Gain Therapeutics (GANX) Cash & Current Investments (2020 - 2026)

Gain Therapeutics' Cash & Current Investments history runs 7 years deep, the most recent figure standing at $16.5 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 82.35% year-over-year to $16.5 million; the TTM figure through Mar 2026 stood at $16.5 million (up 82.35% YoY), while the FY2025 annual figure was $20.8 million, up 100.63% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $16.5 million, down from $20.8 million in the prior quarter.
• The five-year high for Cash & Current Investments was $34.3 million in Q1 2022, with the low at $6.7 million in Q2 2025.
• The 5-year median for Cash & Current Investments is $16.5 million (2026), against an average of $16.4 million.
• Peak annual rise in Cash & Current Investments reached 100.63% in 2025, while the deepest fall reached 60.47% in 2025.
• Gain Therapeutics' Cash & Current Investments stood at $20.1 million in 2022, then declined by 16.6% to $16.8 million in 2023, then sank by 38.16% to $10.4 million in 2024, then soared by 100.63% to $20.8 million in 2025, then declined by 20.63% to $16.5 million in 2026.
• Business Quant data shows GANX's Cash & Current Investments at $16.5 million in Q1 2026, $20.8 million in Q4 2025, and $8.8 million in Q3 2025.